Alanis Therapeutics, a spin out of the San Diego antibody engineering company AvantGen, is harnessing the potential of antibody-based therapeutics to target novel pathways and develop new agents to treat cancer and autoimmunity. Our lead product, ATI-D1, is an antibody that inhibits notch1 signaling between osteoblasts and leukemic stem cells-a key oncogenic driver of tumor progression in MDS/AML. The Company also has an option to expand its pipeline with other AvantGen products which include novel bi- and tri-specific antibodies designed to engage immune cells to treat malignancies or autoimmunity.
